Suppr超能文献

衰老和肿瘤清除是由小鼠肝癌中p53的恢复触发的。

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

作者信息

Xue Wen, Zender Lars, Miething Cornelius, Dickins Ross A, Hernando Eva, Krizhanovsky Valery, Cordon-Cardo Carlos, Lowe Scott W

机构信息

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.

出版信息

Nature. 2007 Feb 8;445(7128):656-60. doi: 10.1038/nature05529. Epub 2007 Jan 24.

Abstract

Although cancer arises from a combination of mutations in oncogenes and tumour suppressor genes, the extent to which tumour suppressor gene loss is required for maintaining established tumours is poorly understood. p53 is an important tumour suppressor that acts to restrict proliferation in response to DNA damage or deregulation of mitogenic oncogenes, by leading to the induction of various cell cycle checkpoints, apoptosis or cellular senescence. Consequently, p53 mutations increase cell proliferation and survival, and in some settings promote genomic instability and resistance to certain chemotherapies. To determine the consequences of reactivating the p53 pathway in tumours, we used RNA interference (RNAi) to conditionally regulate endogenous p53 expression in a mosaic mouse model of liver carcinoma. We show that even brief reactivation of endogenous p53 in p53-deficient tumours can produce complete tumour regressions. The primary response to p53 was not apoptosis, but instead involved the induction of a cellular senescence program that was associated with differentiation and the upregulation of inflammatory cytokines. This program, although producing only cell cycle arrest in vitro, also triggered an innate immune response that targeted the tumour cells in vivo, thereby contributing to tumour clearance. Our study indicates that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.

摘要

尽管癌症源于癌基因和肿瘤抑制基因的突变组合,但维持已形成肿瘤所需的肿瘤抑制基因缺失程度仍知之甚少。p53是一种重要的肿瘤抑制因子,通过诱导各种细胞周期检查点、凋亡或细胞衰老,对DNA损伤或有丝分裂原性癌基因的失调作出反应,从而限制细胞增殖。因此,p53突变会增加细胞增殖和存活,并在某些情况下促进基因组不稳定和对某些化疗的抗性。为了确定在肿瘤中重新激活p53通路的后果,我们使用RNA干扰(RNAi)在肝癌的嵌合小鼠模型中条件性调节内源性p53表达。我们发现,即使在p53缺陷肿瘤中短暂重新激活内源性p53也能使肿瘤完全消退。对p53的主要反应不是凋亡,而是涉及诱导与分化和炎性细胞因子上调相关的细胞衰老程序。该程序虽然在体外仅导致细胞周期停滞,但也在体内触发了针对肿瘤细胞的先天免疫反应,从而有助于肿瘤清除。我们的研究表明,p53缺失可能是维持侵袭性癌所必需的,并阐明了细胞衰老程序如何与先天免疫系统共同作用以有效限制肿瘤生长。

相似文献

1
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
Nature. 2007 Feb 8;445(7128):656-60. doi: 10.1038/nature05529. Epub 2007 Jan 24.
2
Restoration of p53 function: a new therapeutic strategy to induce tumor regression?
Hepatology. 2007 Jun;45(6):1578-9. doi: 10.1002/hep.21789.
4
UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
J Pathol. 2015 Mar;235(4):656-67. doi: 10.1002/path.4478. Epub 2015 Jan 7.
7
Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer.
Am J Pathol. 2017 Feb;187(2):228-235. doi: 10.1016/j.ajpath.2016.09.022. Epub 2016 Dec 7.
9
The role of DNA damage responses in p53 biology.
Arch Toxicol. 2015 Apr;89(4):501-17. doi: 10.1007/s00204-015-1459-z. Epub 2015 Jan 25.
10
Tumour suppression by p53: the importance of apoptosis and cellular senescence.
J Pathol. 2009 Sep;219(1):3-15. doi: 10.1002/path.2584.

引用本文的文献

1
Redefining senescence through hepatocyte fate changes in liver diseases.
Trends Endocrinol Metab. 2025 Aug 28. doi: 10.1016/j.tem.2025.08.003.
2
Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.
Curr Oncol. 2025 Aug 18;32(8):467. doi: 10.3390/curroncol32080467.
3
Immune surveillance of senescent cells in aging and disease.
Nat Aging. 2025 Aug;5(8):1415-1424. doi: 10.1038/s43587-025-00910-5. Epub 2025 Aug 14.
6
Stromal senescence contributes to age-related increases in cancer.
Nat Rev Cancer. 2025 Aug 4. doi: 10.1038/s41568-025-00840-9.
8
New Insights into the Role of Cellular Senescence and Its Therapeutic Implications in Ocular Diseases.
Bioengineering (Basel). 2025 May 23;12(6):563. doi: 10.3390/bioengineering12060563.
9
Future Perspectives in Senescence-Based Therapies for Head and Neck Cancer.
Cancers (Basel). 2025 Jun 12;17(12):1965. doi: 10.3390/cancers17121965.
10
The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers.
Front Immunol. 2025 Jun 9;16:1579832. doi: 10.3389/fimmu.2025.1579832. eCollection 2025.

本文引用的文献

1
Restoration of p53 function leads to tumour regression in vivo.
Nature. 2007 Feb 8;445(7128):661-5. doi: 10.1038/nature05541. Epub 2007 Jan 24.
2
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.
Immunol Rev. 2006 Dec;214:229-38. doi: 10.1111/j.1600-065X.2006.00445.x.
3
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
Nature. 2006 Sep 14;443(7108):214-7. doi: 10.1038/nature05077. Epub 2006 Sep 6.
4
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
Br J Cancer. 2006 Aug 21;95(4):496-505. doi: 10.1038/sj.bjc.6603283. Epub 2006 Aug 1.
5
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors.
Cold Spring Harb Symp Quant Biol. 2005;70:251-61. doi: 10.1101/sqb.2005.70.059.
7
Second-generation shRNA libraries covering the mouse and human genomes.
Nat Genet. 2005 Nov;37(11):1281-8. doi: 10.1038/ng1650. Epub 2005 Oct 2.
8
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.
Nat Genet. 2005 Nov;37(11):1289-95. doi: 10.1038/ng1651. Epub 2005 Oct 2.
10
BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Nature. 2005 Aug 4;436(7051):720-4. doi: 10.1038/nature03890.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验